Literature DB >> 30988577

De Novo JAK2 V617 F Positive AML: The Picture is Getting Clearer.

Kanjaksha Ghosh1, Kinjalka Ghosh2.   

Abstract

Entities:  

Year:  2018        PMID： 30988577      PMCID： PMC6439092          DOI： 10.1007/s12288-018-1041-y

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN： 0971-4502            Impact factor:   0.900


× No keyword cloud information.
  8 in total

1.  Genomic Classification and Prognosis in Acute Myeloid Leukemia.

Authors:  Elli Papaemmanuil; Moritz Gerstung; Hartmut Döhner; Peter J Campbell; Lars Bullinger; Verena I Gaidzik; Peter Paschka; Nicola D Roberts; Nicola E Potter; Michael Heuser; Felicitas Thol; Niccolo Bolli; Gunes Gundem; Peter Van Loo; Inigo Martincorena; Peter Ganly; Laura Mudie; Stuart McLaren; Sarah O'Meara; Keiran Raine; David R Jones; Jon W Teague; Adam P Butler; Mel F Greaves; Arnold Ganser; Konstanze Döhner; Richard F Schlenk
Journal:  N Engl J Med       Date:  2016-06-09       Impact factor: 91.245

2.  Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia.

Authors:  Alireza Eghtedar; Srdan Verstovsek; Zeev Estrov; Jan Burger; Jorge Cortes; Carol Bivins; Stefan Faderl; Alessandra Ferrajoli; Gautam Borthakur; Solly George; Peggy A Scherle; Robert C Newton; Hagop M Kantarjian; Farhad Ravandi
Journal:  Blood       Date:  2012-03-15       Impact factor: 22.113

3.  Morphologic and Molecular Characteristics of De Novo AML With JAK2 V617F Mutation.

Authors:  Juliana E Hidalgo-López; Rashmi Kanagal-Shamanna; L Jeffrey Medeiros; Zeev Estrov; C Cameron Yin; Srdan Verstovsek; Sergej Konoplev; Jeffrey L Jorgensen; Mohammad M Mohammad; Roberto N Miranda; Chong Zhao; John Lee; Zhuang Zuo; Carlos E Bueso-Ramos
Journal:  J Natl Compr Canc Netw       Date:  2017-06       Impact factor: 11.908

4.  JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained.

Authors:  D P Steensma; R F McClure; J E Karp; A Tefferi; T L Lasho; H L Powell; G W DeWald; S H Kaufmann
Journal:  Leukemia       Date:  2006-06       Impact factor: 11.528

5.  JAK2 V617F-positive acute myeloid leukaemia (AML): a comparison between de novo AML and secondary AML transformed from an underlying myeloproliferative neoplasm. A study from the Bone Marrow Pathology Group.

Authors:  Jason Aynardi; Rashmi Manur; Paul R Hess; Seble Chekol; Jennifer J D Morrissette; Daria Babushok; Elizabeth Hexner; Heesun J Rogers; Eric D Hsi; Elizabeth Margolskee; Attilio Orazi; Robert Hasserjian; Adam Bagg
Journal:  Br J Haematol       Date:  2018-05-16       Impact factor: 6.998

Review 6.  JAK2 mutations and clinical practice in myeloproliferative neoplasms.

Authors:  Ayalew Tefferi
Journal:  Cancer J       Date:  2007 Nov-Dec       Impact factor: 3.360

7.  Novel immunophenotypic and morphologic presentation in acute myeloid leukemia (AML) with JAK2 V617F mutation.

Authors:  Suchitra Swaminathan; Manisha Madkaikar; Kanjaksha Ghosh; Babu Rao Vundinti; Lily Kerketta; Maya Gupta
Journal:  Eur J Haematol       Date:  2009-10-12       Impact factor: 2.997

8.  Essential thrombocythemia during treatment of acute myeloid leukemia with JAK2 V617F mutation: A case report of a CARE-compliant article.

Authors:  Wenwen Ding; Danni Li; Chao Zhuang; Pingping Wei; Wenfeng Mou; Lei Zhang; Hui Liang; Yong Liu
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.